170 related articles for article (PubMed ID: 34061965)
1. Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management.
Poma AM; Viola D; Macerola E; Proietti A; Molinaro E; De Vietro D; Elisei R; Materazzi G; Miccoli P; Basolo F; Ugolini C
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4109-e4117. PubMed ID: 34061965
[TBL] [Abstract][Full Text] [Related]
2.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
3. Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.
Na HY; Yu HW; Kim W; Moon JH; Ahn CH; Choi SI; Kim YK; Choi JY; Park SY
Clin Endocrinol (Oxf); 2022 Jul; 97(1):106-115. PubMed ID: 35343605
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
5. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract][Full Text] [Related]
6. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
[TBL] [Abstract][Full Text] [Related]
8. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
[TBL] [Abstract][Full Text] [Related]
9. Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes.
Bikas A; Wong K; Pappa T; Ahmadi S; Wakefield CB; Marqusee E; Xiang P; Altshuler B; Haase J; Barletta JA; Landa I; Alexander EK
Thyroid; 2023 Jun; 33(6):697-704. PubMed ID: 36960703
[No Abstract] [Full Text] [Related]
10. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
11. Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis.
Samankan S; Militello L; Seo G; Everest S; O'Malley Q; Spaulding SL; Xing M; Matloob A; Beute J; Chai R; Doyle S; Urken ML; Brandwein-Weber M
Pathol Res Pract; 2022 Aug; 236():154012. PubMed ID: 35834884
[TBL] [Abstract][Full Text] [Related]
12. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
13. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
14. [
Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of
Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
[No Abstract] [Full Text] [Related]
17. [Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma].
Zhang M; Duan HL; Wang LM; Gao W; Yao YY; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1234-1239. PubMed ID: 34719160
[No Abstract] [Full Text] [Related]
18. Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study.
Ding Z; Tao X; Deng X; Guo B; Kang J; Wu B; Yang Z; Chen C; Liu P; Zhang Y; Fan Y; Liu Z
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6303-6313. PubMed ID: 36735028
[TBL] [Abstract][Full Text] [Related]
19. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma.
Lee SH; Jung CK; Bae JS; Jung SL; Choi YJ; Kang CS
Diagn Cytopathol; 2014 Jan; 42(1):11-7. PubMed ID: 23754825
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]